Nucleo Tech
1 known investors
NucleoTech develops protein carriers called BrainPortal™ that enable therapeutic antibodies and oligonucleotides to cross the blood-brain barrier for treating brain diseases. The company operates a direct in vivo screening platform to discover brain-targeting carriers and licenses them to pharma and biotech partners while advancing internal CNS therapeutics.
BiotechDeep TechMedical Devices